pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

13,366 catalysts · 3,606 8k filing · 2,401 grant · 2,054 approval · 1,400 device 510k · 1,000 device adverse event · 944 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-31: 3 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts2026-11-23: 0 catalysts2026-11-24: 0 catalysts2026-11-25: 0 catalysts2026-11-26: 0 catalysts2026-11-27: 0 catalysts2026-11-28: 0 catalysts2026-11-29: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2025-10-31×clear all
type
  • 8k filing3,606
  • grant2,401
  • approval2,054
  • device 510k1,400
  • device adverse event1,000
  • device recall944
  • device pma932
  • earnings585
  • recall364
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 27, 2026

    50
    ›Apr 28, 2026phase iv trial initiation126d agoRajendra Institute of Medical Sciences — levobupivacaine (Phase IV Trial Initiation)levobupivacaine

    Therapy area: Central Nervous System. Indication: Pain

    full page →levobupivacaine →source: globaldata
    ›Apr 28, 20268k filing126d ago$JNJ — JOHNSON & JOHNSON (JNJ) — 8-K filing

    Items: 5.07, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$GNPX — Genprex, Inc. (GNPX) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$PASG — Passage BIO, Inc. (PASG) — 8-K filing

    Items: 2.05

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$ACRS — Aclaris Therapeutics, Inc. (ACRS) — 8-K filing

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$INCY — INCYTE CORP (INCY) — 8-K filing

    Items: 2.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$AVTX — Avalo Therapeutics, Inc. (AVTX) — 8-K filing

    Items: 1.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$IMUX — IMMUNIC, INC. (IMUX) — 8-K filing

    Items: 5.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$SGMT — Sagimet Biosciences Inc. (SGMT) — 8-K filing

    Items: 1.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$ELAB — PMGC Holdings Inc. (ELAB) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$KNSA — Kiniksa Pharmaceuticals International, plc (KNSA) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$WVE — Wave Life Sciences Ltd. (WVE) — 8-K filing

    Items: 2.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d agoROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) — 8-K filing

    Items: 1.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$SNGX — SOLIGENIX, INC. (SNGX) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$BCDA — BioCardia, Inc. (BCDA) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$ALLR — Allarity Therapeutics, Inc. (ALLR) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d agoSilexion Therapeutics Corp (SLXN, SLXNW) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$BMEA — Biomea Fusion, Inc. (BMEA) — 8-K filing

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$ARAY — ACCURAY INC (ARAY) — 8-K filing

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$CLYM — Climb Bio, Inc. (CLYM) — 8-K filing

    Items: 1.01, 3.02, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$GILD — GILEAD SCIENCES, INC. (GILD) — 8-K filing

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$ACET — Adicet Bio, Inc. (ACET) — 8-K filing

    Items: 3.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$NRC — NRC HEALTH (NRC) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$ACLX — Arcellx, Inc. (ACLX) — 8-K filing

    Items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$DSGN — Design Therapeutics, Inc. (DSGN) — 8-K filing

    Items: 2.02, 7.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$NRC — NRC HEALTH (NRC) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$OPK — OPKO HEALTH, INC. (OPK) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$VTGN — Vistagen Therapeutics, Inc. (VTGN) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$LABT — Lakewood-Amedex Biotherapeutics Inc. (LABT) — 8-K filing

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d agoSeaStar Medical Holding Corp (ICU, ICUCW) — 8-K filing

    Items: 8.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$FLNA — FILANA THERAPEUTICS, INC. (FLNA) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$PTCT — PTC THERAPEUTICS, INC. (PTCT) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$HRGN — Harvard Apparatus Regenerative Technology, Inc. (HRGN) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$MDGL — MADRIGAL PHARMACEUTICALS, INC. (MDGL) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$FENC — FENNEC PHARMACEUTICALS INC. (FENC) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$QNCX — Quince Therapeutics, Inc. (QNCX) — 8-K filing

    Items: 8.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$PREM — Premier Air Charter Holdings Inc. (PREM) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d agoScilex Holding Co (SCLX, SCLXW) — 8-K filing

    Items: 1.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$JANX — Janux Therapeutics, Inc. (JANX) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$CTOR — CITIUS ONCOLOGY, INC. (CTOR) — 8-K filing

    Items: 3.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$QUCY — Quantum Cyber N.V. (QUCY) — 8-K filing

    Items: 1.01, 3.02, 5.01, 5.02, 5.03, 5.07, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$GRDX — GridAI Technologies Corp. (GRDX) — 8-K filing

    Items: 3.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing126d ago$LNAI — Lunai Bioworks Inc. (LNAI) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 2026pdufa125d agoSanofi — teplizumab (PDUFA)teplizumab

    Therapy area: Metabolic Disorders. Indication: Type 1 Diabetes (Juvenile Diabetes)

    full page →teplizumab →source: globaldata
    ›Apr 29, 2026phase 0 trial completion125d agoDana-Farber Cancer Institute Inc — atezolizumab (Phase 0 Trial Completion)atezolizumab

    Therapy area: Oncology. Indication: Hepatocellular Carcinoma, Liver Cancer

    full page →atezolizumab →source: globaldata
    ›Apr 29, 2026phase 1 completion125d agoBoehringer Ingelheim International GmbH — BI-765179 (Phase I Trial Completion)BI-765179

    Therapy area: Oncology. Indication: Cervical Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer, Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hepatocellular Carcinoma, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Pleural Mesothelioma, Melanoma, Non-Small Cell Lung Carcinoma, Oral Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Re

    full page →BI-765179 →source: globaldata
    ›Apr 29, 2026phase 1 completion125d agoUniversity of Washington — autologous mitochondria (Phase I Trial Completion)autologous mitochondria

    Therapy area: Cardiovascular. Indication: Cerebrovascular Disease, Ischemia

    full page →autologous mitochondria →source: globaldata
    ›Apr 29, 2026phase 1 completion125d agoAltasciences Co Inc — NN-7442 (Phase I Trial Completion)NN-7442

    Therapy area: Hematological Disorders. Indication: Hemophilia A (Factor VIII Deficiency)

    full page →NN-7442 →source: globaldata
    ›Apr 29, 2026phase 1 initiation125d agoTerSera Therapeutics LLC — goserelin LA (Phase I Trial Initiation)goserelin LA

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

    full page →goserelin LA →source: globaldata
    ›Apr 29, 2026phase 1 initiation125d agoOcugen Inc — adenovirus vector (spike protein) vaccine (Phase I Trial Initiation)adenovirus vector (spike protein) vaccine

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19)

    full page →adenovirus vector (spike protein) vaccine →source: globaldata
    ← prev
    page 192 of 268
    next →
    $OCGN1.2800-2.29%
    $SNY44.82-0.04%